BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20663481)

  • 1. The tuberculosis structural genomics consortium: a structural genomics approach to drug discovery.
    Musa TL; Ioerger TR; Sacchettini JC
    Adv Protein Chem Struct Biol; 2009; 77():41-76. PubMed ID: 20663481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural genomics approach to drug discovery for Mycobacterium tuberculosis.
    Ioerger TR; Sacchettini JC
    Curr Opin Microbiol; 2009 Jun; 12(3):318-25. PubMed ID: 19481971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
    Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
    Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential impact of structural genomics on tuberculosis drug discovery.
    Arcus VL; Lott JS; Johnston JM; Baker EN
    Drug Discov Today; 2006 Jan; 11(1-2):28-34. PubMed ID: 16478688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing the structural coverage of tuberculosis drug targets.
    Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
    Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
    Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
    Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput crystallography at an affordable cost: the TB Structural Genomics Consortium Crystallization Facility.
    Rupp B
    Acc Chem Res; 2003 Mar; 36(3):173-81. PubMed ID: 12641474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.
    Lou Z; Zhang X
    Protein Cell; 2010 May; 1(5):435-42. PubMed ID: 21203958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug discovery in tuberculosis: a molecular approach.
    Mitra PP
    Indian J Tuberc; 2012 Oct; 59(4):194-206. PubMed ID: 23342539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Mycobacterium tuberculosis structural genomics: investigating potential chinks in the armor of a deadly pathogen.
    Chim N; McMath LM; Beeby M; Goulding CW
    Infect Disord Drug Targets; 2009 Nov; 9(5):475-92. PubMed ID: 19594421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural genomics of Mycobacterium tuberculosis: a preliminary report of progress at UCLA.
    Goulding CW; Perry LJ; Anderson D; Sawaya MR; Cascio D; Apostol MI; Chan S; Parseghian A; Wang SS; Wu Y; Cassano V; Gill HS; Eisenberg D
    Biophys Chem; 2003 Sep; 105(2-3):361-70. PubMed ID: 14499904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterium tuberculosis: a model system for structural genomics.
    Smith CV; Sacchettini JC
    Curr Opin Struct Biol; 2003 Dec; 13(6):658-64. PubMed ID: 14675542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TB structural genomics consortium: providing a structural foundation for drug discovery.
    Goulding CW; Apostol M; Anderson DH; Gill HS; Smith CV; Kuo MR; Yang JK; Waldo GS; Suh SW; Chauhan R; Kale A; Bachhawat N; Mande SC; Johnston JM; Lott JS; Baker EN; Arcus VL; Leys D; McLean KJ; Munro AW; Berendzen J; Sharma V; Park MS; Eisenberg D; Sacchettini J; Alber T; Rupp B; Jacobs W; Terwilliger TC
    Curr Drug Targets Infect Disord; 2002 Jun; 2(2):121-41. PubMed ID: 12462144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.
    Almeida Da Silva PE; Palomino JC
    J Antimicrob Chemother; 2011 Jul; 66(7):1417-30. PubMed ID: 21558086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
    Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
    Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensively drug-resistant tuberculosis: current challenges and threats.
    Jain A; Mondal R
    FEMS Immunol Med Microbiol; 2008 Jul; 53(2):145-50. PubMed ID: 18479439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An
    Kumar S; Sahu P; Jena L
    Int J Mycobacteriol; 2019; 8(3):252-261. PubMed ID: 31512601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New tuberculosis drugs on the horizon.
    Cole ST; Riccardi G
    Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Annotation of the Mycobacterium tuberculosis Proteome.
    Chandra N; Sandhya S; Anand P
    Microbiol Spectr; 2014 Apr; 2(2):. PubMed ID: 26105824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.